Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in MSI-H colorectal cancer
NCT02060188Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2014
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label trial of nivolumab in colorectal cancer (CRC) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate up to 127 months. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02060188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060188.